Compare Abbott Laboratories (ABT) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Booking Holdings Inc — how do they compare? Abbott Laboratories trades at $110.99 (market cap $187.95B), while Booking Holdings Inc trades at $211.61 (market cap $159.95B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | BKNG | |
|---|---|---|
Market Cap | $187.95B | $159.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $228.83 |
52-Week Low | $82.57 | $154.13 |
Enterprise Value | $214.96B | $163.43B |
Dividend Yield | 2.32% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Booking Holdings (BKNG) trades at $211.73, down 0.54% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates at $2.54 versus $2.43 expected, driven by resilient travel demand. Revenue grew to $26.92B in 2025, with a net income margin of 25.53%, while cash flow from operations remains robust at $9.41B. Analyst consensus is strongly bullish with a $239.31 price target.
Outlook is positive given earnings beats and travel recovery, but risks include geopolitical volatility and high valuation multiples. The stock offers growth potential with a wide moat in online travel, though debt levels and competitive pressures warrant monitoring. Institutional sentiment supports upside, with 64% of analysts rating it Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
